MedaSystems

MedaSystems' platform provides life science companies with a configurable workflow generator, flexible forms for data capture, a secure open architecture and automatic audit log, allowing the rapid deployment of Expanded Access, Post-Trial Access and Investigator Initiated Study Programs.

The page covers Expanded Access and Compassionate Use programs, including program types, operations, and ethical considerations.

The page discusses which capabilities biopharmaceutical companies should develop internally and which are best supported by external expertise and technology partners as expanded access and managed access programs become more important to patient access strategy.

Expanded Access Programs (EAPs), also called compassionate use programs, provide a regulatory pathway for patients to receive investigational treatments outside clinical trials while awaiting regulatory approval.

Investigator-Initiated Studies (IIS) programs are becoming more strategic, data-driven, patient-centered, and digitally enabled in 2026 as organizations adapt to changing research demands.

MedaSystems offers jobs on a team that helps patients apply for expanded access or compassionate use of experimental therapies.

The company has years of experience helping patients, physicians, and pharmaceutical companies streamline compassionate use requests.

Today, MedaSystems' software is trusted by pharmaceutical companies across the United States and Europe to enhance patient outcomes and streamline the management

MedaSystems offers a SaaS platform to streamline compassionate use or expanded access requests.

The cloud platform supports global expanded and managed access programs, enabling collaboration with healthcare providers, approval decisions, reduced manual steps, regulatory compliance, and real-world data capture.

The company’s privacy policy describes how it collects and uses data.

The page contains terms for the application when it is in use.